Treatment strategy involving docetaxel plus cisplatin and 5-fluorouracil followed by conversion surgery for locally advanced unresectable/borderline resectable esophageal squamous cell carcinoma
Diseases of the Esophagus · 2025
DOI: 10.1093/dote/doae114 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diseases of the Esophagus, 2025. Verfasst von Shota Igaue und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Esophageal Surgery, National Cancer Center, Tokyo, Japan. Hauptthemen laut MEDLINE: Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Esophagectomy. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 27 Literaturangaben.
Abstract (Originalsprache)
Definitive chemoradiotherapy (dCRT) is the standard treatment for unresectable (T4) esophageal squamous cell carcinoma (ESCC), but the prognosis is poor. Borderline resectable (T3br) ESCC has been discussed, but its clinical features and appropriate treatment are unclear. The effects of docetaxel plus cisplatin and 5-fluorouracil (DCF) therapy and subsequent surgery for potentially unresectable ESCC remain controversial. This was a single-center retrospective cohort study. Patients with T3 or deeper ESCC lesions between January 2017 and June 2020 were examined. We identified T3br/T4 ESCC patients who initially received DCF therapy or dCRT, and analyzed the long-term outcomes of these patients. Seventy-four patients with T3br/T4 ESCC were identified. Forty-four patients initially received DCF therapy, while thirty initially received dCRT. The 3-year overall survival of T3br/T4 patients in the DCF group was better than that in the dCRT group (62.9% vs. 34.1%, P = 0.001). In the T3br cohort, 95.8% of patients underwent surgery after DCF therapy, with an R0 resection rate of 78.3%. In the T4 group, 40% of patients underwent surgery after DCF, with a 75.0% R0 resection rate. No cases of reoperation or in-hospital death occurred. For both subgroups, T3br and T4, the prognosis tended to be better in the DCF group than in the dCRT group. This study explored real-world data from T3br/T4 ESCC patients who initially received DCF and subsequent surgery and revealed that DCF is a promising treatment strategy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Esophageal Surgery, National Cancer Center, Tokyo, Japan.
- Course of Advanced Clinical Research of Cancer, Juntendo University Graduate School of Medicine, Tokyo, Japan.
- Department of Head and Neck, Esophageal Medical Oncology, National Cancer Center, Tokyo, Japan.
- Department of Diagnostic Radiology, National Cancer Center, Tokyo, Japan.
ORCID-Profile: Hiroyuki Daiko
Zitieren
APA
Igaue, S., Nozaki, R., Utsunomiya, D., Kubo, Y., Kubo, K., Kurita, D., Yamamoto, S., Miyake, M., Ishiyama, K., Oguma, J., Kato, K., & Daiko, H. (2025). Treatment strategy involving docetaxel plus cisplatin and 5-fluorouracil followed by conversion surgery for locally advanced unresectable/borderline resectable esophageal squamous cell carcinoma. Diseases of the Esophagus. https://doi.org/10.1093/dote/doae114
Vancouver
Igaue S, Nozaki R, Utsunomiya D, Kubo Y, Kubo K, Kurita D, et al. Treatment strategy involving docetaxel plus cisplatin and 5-fluorouracil followed by conversion surgery for locally advanced unresectable/borderline resectable esophageal squamous cell carcinoma. Diseases of the Esophagus. 2025. doi:10.1093/dote/doae114
BibTeX
@article{Igaue2025,
author = {Igaue, Shota and Nozaki, Ryoko and Utsunomiya, Daichi and Kubo, Yuto and Kubo, Kentaro and Kurita, Daisuke and Yamamoto, Shun and Miyake, Mototaka and Ishiyama, Koshiro and Oguma, Junya and Kato, Ken and Daiko, Hiroyuki},
title = {Treatment strategy involving docetaxel plus cisplatin and 5-fluorouracil followed by conversion surgery for locally advanced unresectable/borderline resectable esophageal squamous cell carcinoma},
journal = {Diseases of the Esophagus},
year = {2025},
doi = {10.1093/dote/doae114}
}
EUVIMED